论文部分内容阅读
为探讨心钠素在肝硬变腹水中的治疗效应,本工作应用人工合成的人心房肽Ⅲ(human Atriopeptin Ⅲ,hAPⅢ,心钠素)治疗8例肝硬变腹水患者,并进行了利尿、利钠等疗效观察.结果发现:静注200μg hAPⅢ后第1小时尿量和尿钠排泄均较对照显著增加,分别由注射前38.83±5.76 ml/h和2.44±0.55 mmol/h增至74.33±12.89 ml/h和5.12±1.07 mmol/h(P<0.05);且尿量、尿钠排泄增加可持续3～4小时;同时观察的尿钾、尿氯排泄量亦有增加;给药60min后肾素—血管紧张素—醛固酮(RAAS),有一定程度的抑制,但未发现统计学差异;血压、心率和血电解质无明显变化.实验结果表明,应用hAPⅢ治疗肝硬变腹水有明显的利尿、利钠作用,由于其只有轻度排钾、排氯作用,在某些方面.优于排钾利尿剂.
In order to explore the therapeutic effect of atrial natriuretic peptide in cirrhosis ascites, 8 cases of ascites due to liver cirrhosis were treated with synthetic human atriopeptin Ⅲ (hAP Ⅲ, atrial natriuretic peptide) Sodium and other effects were observed.Results: After intravenous injection of 200μg hAP Ⅲ first hour urine output and urinary sodium excretion were significantly increased from 38.83 ± 5.76 ml / h and 2.44 ± 0.55 mmol / h before injection to 74.33 ± 12.89 ml / h and 5.12 ± 1.07 mmol / h respectively (P <0.05). Urine excretion and urinary sodium excretion increased for 3 ~ 4 hours. Urinary potassium and urinary excretion of urinary excretion also increased. Renin - angiotensin - aldosterone (RAAS), to a certain extent, but no statistical difference was found.The blood pressure, heart rate and blood electrolytes had no significant changes.Experimental results show that the application of hAP Ⅲ in the treatment of liver cirrhosis with significant diuresis , Sodium role, because it is only a slight row of potassium, chlorine role in some areas. Outperform potassium diuretics.